The Destiny Breast 11 trial compared a new drug to a chemotherapy regimen (ACTHP) that many US oncologists no longer use. This choice of a less common control arm makes it difficult for them to directly compare the new treatment's efficacy against their own current standard (TCHP), complicating adoption.

The standard of care for melanoma is improving so quickly that control arms in recent clinical trials are significantly outperforming historical data. This 'rising tide' effect makes it increasingly difficult for new drugs to show a statistically significant benefit, creating high unpredictability for developers.

The Sac o six nineteen trial showed compelling results adding BCG to a chemo-immunotherapy backbone. However, the standard of care has already shifted to a newer combination (enfortumab vedotin and pembrolizumab), making it difficult to translate the study's findings into current practice and complicating the design of future trials.

The current pace of innovation in CLL treatment means new options become available faster than long-term clinical trials can conclude. This creates a critical need for more efficient trial designs and validated intermediate endpoints that can provide reliable answers sooner.

The LIDERA trial's success is complicated because it was designed against a standard of care that is now outdated. It excluded CDK4/6 inhibitors, which are now common for high-risk patients, creating a gap in understanding how to integrate this new drug into modern clinical practice.

Clinicians identify outdated control arms—like single-agent chemotherapy without newer targeted agents—as a major deterrent for patient trial participation. Patients are unwilling to be randomized to a therapy that doesn't reflect the current, more effective standard of care. This pressure is forcing sponsors and the FDA to design trials with more realistic comparator arms.

Comparing control arms from the TOGA (11 months OS), KEYNOTE-811 (16 months), and HORIZON (19 months) trials reveals a steady improvement in patient outcomes. This trend, likely due to better second-line therapies and supportive care, makes it harder for new agents to show a relative benefit.

The pace of new drug approvals in oncology means that established clinical trial control arms, often using older chemotherapies, may no longer represent the true standard of care. This discrepancy can deter patient enrollment and challenges trial designers to remain nimble and current.

As effective treatments like EV Pembro become the standard of care in oncology, it is no longer ethically feasible to conduct randomized trials for new "me-too" drugs against the outdated platinum chemotherapy standard in many markets. This severely limits development pathways for fast-follower drugs.